After a patient's death, the FDA has suspended two Phase 1 trials assessing Cellectis’ CAR T-cell therapy UCART123 in AML and BPDCN.

Immune checkpoint inhibitors work to block two proteins – PD-1 or CTLA-4 – that cancer cells use to evade immune system protector cells called T-cells.

The FDA has approved Imfinzi in combination with standard chemotherapy as a first-line treatment of people with metastatic small cell lung cancer.

A new immunotherapy strategy using CAR T-cells activated by light effectivelly kills cancer cells in mice and may reduce treatment side effects in people.

Keytruda has been approved in China as a second-line therapy for people with advanced esophageal squamous cell carcinoma (ESCC).

Learn more about DNX-2401, an oncolytic immunotherapy being investigated by DNAtrix for the treatment of cancers, especially brain tumors.

Learn more about oncolytic virus therapy (OVT), a promising treatment approach that uses a virus to infect and destroy cancer cells, but not normal cells.

Tecentriq-Avastin extends survival and the time without disease progression in newly-diagnosed, inoperable hepatocellular carcinoma patients, a study shows.

The FDA granted its breakthrough therapy designation to Immunocore's tebentafusp for uveal melanoma, a common but hard-to-treat form of eye cancer.

A planned safety review of a Phase 2 trial evaluating MDNA55 to treat glioblastoma has shown that the drug, developed by Medicenna Therapeutics is safe to deliver precisely into a patient’s tumor, ...

Read why James Allison and Tasuku Honjo, won the 2018 Nobel Prize in Medicine for their research on cancer immunotherapy.

Read about the immuno-oncology therapy PF-06801591, which works by targeting a protein found on the surface of a range of cancers.